Lab Med Online.  2015 Oct;5(4):196-203. 10.3343/lmo.2015.5.4.196.

Neonatal Screening Tests for Inherited Metabolic Disorders using Tandem Mass Spectrometry: Experience of a Clinical Laboratory in Korea

• Cho SE
• Park EJ
• Seo DH
• Lee IB
• Lee HJ
• Cho DY
• Oh JM

• KMID: 2046381
• DOI: http://doi.org/10.3343/lmo.2015.5.4.196

Abstract

BACKGROUND
The purpose of this study is to investigate the positive rates of screening tests for inherited metabolic disorders, set cutoff values, and report the actual status of internal quality controls in LabGenomics Clinical Laboratories by using LC-MS/MS system.
METHODS
We use Agilent 1260 Infinity HPLC System (Agilent Technologies, USA) for liquid chromatography, and API 2000 (AB Sciex, Canada) for MS/MS system. We set up screening tests for 55 diseases, which include metabolic disorders of 25 amino acids, 16 organic acids, and 14 fatty acids.
RESULTS
We determined the analyte cutoff values as 99.9 or 0.1 percentiles in 15,000 newborn samples. The total number of samples tested from January 2012 to September 2014 was 119,948; of these, 6,681 were repeated. Of the repeated samples, 713 were presumed to be positive in the screening tests. Repeat screening with newly obtained dried blood spot specimens was recommended for these 713 samples and 600 specimens were obtained. Thus, the recall rate was 0.5% (600/119,948) for all samples and 84.2% (600/713) for the samples presumed to be positive in the screening tests. About 70 samples, that is, 0.06% of the total samples and 11.7% of the "reobtained" samples, again tested positive; we recommended confirmatory tests for these samples.
CONCLUSIONS
We have presented data on the status of neonatal screening tests for inherited metabolic disorders using LC-MS/MS, including positive rates and recall rates of screening tests, set up cutoff values and reported the actual status of internal quality controls in a clinical laboratory in Korea.

Keyword

Neonatal screening; Inherited metabolic disorders; Tandem mass spectrometry

MeSH Terms

Amino Acids
Chromatography, High Pressure Liquid
Chromatography, Liquid
Fatty Acids
Humans
Infant, Newborn
Korea*
Mass Screening
Neonatal Screening*
Quality Control
Tandem Mass Spectrometry*
Amino Acids
Fatty Acids

Reference

1. Ministry of Health & Wefare. Korea Population and Health Welfare Association. Blood sample records for neonatal screening test and external quality assessment for inborn errors of metabolism in Korea, 2013.

2. Clinical and Laboratory Standards Institute. Newborn screening for preterm, low birth weight, and sick newborns; approved guideline. CLSI document NBS03-A (Replaces I/LA 31-P). Wayne PA: Clinical and Laboratory Standards Institute;2009.

3. Clinical and Laboratory Standards Institute. Newborn screening by tandem mass spectrometry; approved guideline. CLSI document NBS04-A (formerly I/LA32-A). Wayne PA: Clinical and Laboratory Standards Institute;2010.

4. Yoon HR, Lee KR, Kang S, Lee DH, Yoo HW, Min WK, et al. Screening of newborns and high-risk group of children for inborn metabolic disorders using tandem mass spectrometry in South Korea: a three-year report. Clin Chim Acta. 2005; 354:167–180.

5. Zytkovicz TH, Fitzgerald EF, Marsden D, Larson CA, Shih VE, Johnson DM, et al. Tandem mass spectrometric analysis for amino, organic, and fatty acid disorders in newborn dried blood spots: a two-year summary from the New England Newborn Screening Program. Clin Chem. 2001; 47:1945–1955.

6. CDC cutoffs. Newborn screening quality assurance program. Quarterly Report Tandem Mass Spectrometry 2014 quarter 4. https://wwwn.cdc.gov/NSQAP/Restricted/CDCCutOffs.aspx.

7. McHugh D, Cameron CA, Abdenur JE, Abdulrahman M, Adair O, Al Nuaimi SA, et al. Clinical validation of cutoff target ranges in newborn screening of metabolic disorders by tandem mass spectrometry: a worldwide collaborative project. Genet Med. 2011; 13:230–254.

8. Marquardt G, Currier R, McHugh DM, Gavrilov D, Magera MJ, Matern D, et al. Enhanced interpretation of newborn screening results without analyte cutoff values. Genet Med. 2012; 14:648–655.

9. http://www.clir-r4s.org/Default.aspx.

10. Song SM, Yoon HR, Lee AN, Lee KR. Seven-year experience with inherited metabolic disorders screening by tandem mass spectrometry. J Genet Med. 2008; 5:21–25.

11. Lee EH. Inherited metabolic disorders screening by tandem mass spectrometry: assessment and future prospect through two-year experience. J Genet Med. 2003; 3:94–96.

12. Yu CL, Gu XF. Newborn screening of inherited metabolic diseases by tandem mass spectrometry. Beijing Da Xue Xue Bao. 2006; 38:103–106.

13. Niu DM, Chien YH, Chiang CC, Ho HC, Hwu WL, Kao SM, et al. Nationwide survey of extended newborn screening by tandem mass spectrometry in Taiwan. J Inherit Metab Dis. 2010; 33:S295–S305.

14. Levy PA. An overview of newborn screening. J Dev Behav Pediatr. 2010; 31:622–631.

15. Brusilow SW, Maestri NE. Urea cycle disorders: diagnosis, pathophysiology, and therapy. Adv Pediatr. 1996; 43:127–170.

16. Clinical and Laboratory Standards Institute. Newborn screening follow-up; approved guideline. CLSI document NBS02-A2 (replaces I/LA 27-A). Wayne PA: Clinical and Laboratory Standards Institute;2013.

17. Lee YW, Lee DH, Vockley J, Kim ND, Lee YK, Ki CS. Different spectrum of mutations of isovaleryl-CoA dehydrogenase (IVD) gene in Korean patients with isovaleric acidemia. Mol Genet Metab. 2007; 92:71–77.

18. Lee YW, Lee DH, Kim ND, Lee ST, Ahn JY, Choi TY, et al. Mutation analysis of PAH gene and characterization of a recurrent deletion mutation in Korean patients with phenylketonuria. Exp Mol Med. 2008; 40:533–540.

19. Park HD, Lee DH, Choi TY, Lee YK, Kim JW, Ki CS, et al. Clinical, biochemical, and genetic analysis of a Korean neonate with hereditary tyrosinemia type 1. Clin Chem Lab Med. 2009; 47:930–933.

20. Woo HI, Park HD, Lee YW, Lee DH, Ki CS, Lee SY, et al. Clinical, biochemical and genetic analyses in two Korean patients with medium-chain acyl-CoA dehydrogenase deficiency. Korean J Lab Med. 2011; 31:54–60.

21. Park HD, Lee DH, Hong YH, Kang DH, Lee YK, Song J, et al. Three Korean patients with maple syrup urine disease: four novel mutations in the BCKDHA gene. Ann Clin Lab Sci. 2011; 41:167–173.

22. Kim HJ, Park SJ, Park KI, Lee JS, Eun HS, Kim JH, et al. Acute treatment of hyperammonemia by continuous renal replacement therapy in a newborn patient with ornithine transcarbamylase deficiency. Korean J Pediatr. 2011; 54:425–428.

23. Woo HI, Ki CS, Lee SY, Kim JW, Song J, Jin DK, et al. Mutation spectrum of the ASS1 gene in Korean patients with citrullinemia type 1. Clin Biochem. 2013; 46:209–213.

24. Forman J, Coyle F, Levy-Fisch J, Roberts P, Terry S, Legge M. Screening criteria: the need to deal with new developments and ethical issues in newborn metabolic screening. J Community Genet. 2013; 4:59–67.